• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach.

作者信息

Pugliese Giusj Monia, Venafra Veronica, Bica Valeria, Massacci Giorgia, Latini Sara, Graziosi Simone, Fischer Thomas, Mougiakakos Dimitrios, Boettcher Martin, Perfetto Livia, Sacco Francesca

机构信息

Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133, Rome, Italy.

Institute of Molecular and Clinical Immunology, University of Magdeburg, Magdeburg, Germany.

出版信息

Leukemia. 2023 May;37(5):1151-1155. doi: 10.1038/s41375-023-01881-5. Epub 2023 Mar 25.

DOI:10.1038/s41375-023-01881-5
PMID:36966261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10169656/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bee/10169656/1ba5e2c7ea1d/41375_2023_1881_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bee/10169656/993b1c745d92/41375_2023_1881_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bee/10169656/1ba5e2c7ea1d/41375_2023_1881_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bee/10169656/993b1c745d92/41375_2023_1881_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bee/10169656/1ba5e2c7ea1d/41375_2023_1881_Fig2_HTML.jpg

相似文献

1
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach.FLT3-ITD 位置对急性髓系白血病中阿糖胞苷敏感性的影响：一种基于网络的方法。
Leukemia. 2023 May;37(5):1151-1155. doi: 10.1038/s41375-023-01881-5. Epub 2023 Mar 25.
2
Cytarabine-Resistant -ITD Leukemia Cells are Associated with Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib.阿糖胞苷耐药-ITD 白血病细胞与突变和多个信号通路改变相关-卡博替尼可能具有治疗效果。
Int J Mol Sci. 2019 Mar 11;20(5):1230. doi: 10.3390/ijms20051230.
3
Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.西达本胺治疗 FLT3-ITD 阳性急性髓系白血病及其与阿糖胞苷的协同作用。
Biomed Pharmacother. 2017 Jun;90:699-704. doi: 10.1016/j.biopha.2017.04.037. Epub 2017 Apr 15.
4
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.与具有FLT3内部串联重复的急性髓系白血病母细胞相比，具有FLT3酪氨酸激酶结构域突变的急性髓系白血病母细胞对来他替尼的敏感性较低。
Br J Haematol. 2008 May;141(4):454-60. doi: 10.1111/j.1365-2141.2008.07025.x. Epub 2008 Mar 12.
5
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.Pim激酶抑制通过增加DNA损伤和氧化应激使FLT3-ITD急性髓系白血病细胞对拓扑异构酶2抑制剂敏感。
Oncotarget. 2016 Jul 26;7(30):48280-48295. doi: 10.18632/oncotarget.10209.
6
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.通过不同的联合用药策略逆转FLT3突变的急性髓系白血病细胞中的获得性耐药
Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.
7
ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.ULK1 抑制作为 FLT3-ITD 突变型急性髓系白血病的靶向治疗策略。
J Exp Clin Cancer Res. 2020 May 11;39(1):85. doi: 10.1186/s13046-020-01580-4.
8
Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.米哚妥林联合标准化疗治疗新诊断的FMS样酪氨酸激酶3（FLT3）突变阳性急性髓系白血病。
Ann Pharmacother. 2018 Apr;52(4):364-369. doi: 10.1177/1060028017747900. Epub 2017 Dec 12.
9
Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.2-脱氧-D-葡萄糖通过抑制FLT3-ITD或c-KIT突变的急性髓系白血病中的N-连接糖基化发挥抗白血病活性。
Mol Cancer Ther. 2015 Oct;14(10):2364-73. doi: 10.1158/1535-7163.MCT-15-0163. Epub 2015 Jul 23.
10
FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.FLT3-ITD 通过调节 DNA 修复途径与 Rac1 合作调节白血病细胞对化疗药物的敏感性。
Haematologica. 2019 Dec;104(12):2418-2428. doi: 10.3324/haematol.2018.208843. Epub 2019 Apr 11.

引用本文的文献

1
SignalingProfiler 2.0 a network-based approach to bridge multi-omics data to phenotypic hallmarks.SignalingProfiler 2.0：一种基于网络的方法，用于将多组学数据与表型特征联系起来。
NPJ Syst Biol Appl. 2024 Aug 23;10(1):95. doi: 10.1038/s41540-024-00417-6.
2
Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction.揭示 FLT3-ITD AML 的信号转导网络可提高药物敏感性预测。
Elife. 2024 Apr 2;12:RP90532. doi: 10.7554/eLife.90532.
3
How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia.

本文引用的文献

1
A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.WEE1-CDK1 轴在介导 FLT3-ITD 阳性急性髓系白血病患者对 TKI 治疗耐药中的关键作用。
Leukemia. 2023 Feb;37(2):288-297. doi: 10.1038/s41375-022-01785-w. Epub 2022 Dec 12.
2
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
3
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
内部串联重复（ITD）插入位点如何调控FLT3-ITD突变型急性髓系白血病的生物学特性及疾病发生
Cancers (Basel). 2023 May 30;15(11):2991. doi: 10.3390/cancers15112991.
急性髓系白血病中FLT3-ITD插入位点的分子图谱及预后影响：RATIFY研究结果
Leukemia. 2022 Jan;36(1):90-99. doi: 10.1038/s41375-021-01323-0. Epub 2021 Jul 28.
4
Combining Mass Spectrometry-Based Phosphoproteomics with a Network-Based Approach to Reveal FLT3-Dependent Mechanisms of Chemoresistance.结合基于质谱的磷酸化蛋白质组学与基于网络的方法以揭示FLT3依赖性化疗耐药机制。
Proteomes. 2021 Apr 27;9(2):19. doi: 10.3390/proteomes9020019.
5
THZ1, a covalent CDK7 inhibitor, enhances gemcitabine-induced cytotoxicity via suppression of Bcl-2 in urothelial carcinoma.THZ1，一种共价CDK7抑制剂，通过抑制膀胱尿路上皮癌中的Bcl-2增强吉西他滨诱导的细胞毒性。
Am J Cancer Res. 2021 Jan 1;11(1):171-180. eCollection 2021.
6
Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia.急性髓系白血病中的分子靶向与合理化疗
J Exp Pharmacol. 2020 May 29;12:107-128. doi: 10.2147/JEP.S254334. eCollection 2020.
7
Targeting FLT3 mutations in AML: review of current knowledge and evidence.AML 中 FLT3 突变的靶向治疗：现有知识和证据的综述。
Leukemia. 2019 Feb;33(2):299-312. doi: 10.1038/s41375-018-0357-9. Epub 2019 Jan 16.
8
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.酪氨酸激酶抑制剂诱导的 DNA 修复缺陷使 FLT3(ITD)阳性白血病细胞对 PARP1 抑制剂敏感。
Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21.
9
Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition.化疗诱导 B 细胞淋巴瘤的细胞周期差异停滞会影响其对 Wee1 抑制的敏感性。
Haematologica. 2018 Mar;103(3):466-476. doi: 10.3324/haematol.2017.175992. Epub 2017 Dec 7.
10
The Perseus computational platform for comprehensive analysis of (prote)omics data.Perseus 计算平台，用于全面分析（蛋白质组学）数据。
Nat Methods. 2016 Sep;13(9):731-40. doi: 10.1038/nmeth.3901. Epub 2016 Jun 27.